What Happened

MoonLake's Phase 3 VELA program showed that 67.2% of adults treated with sonelokimab achieved HiSCR75, with a third reaching HiSCR100. The drug also demonstrated strong efficacy in adolescents, with interim Week 24 results showing 68% HiSCR75 and 45% HiSCR100.

Who Is Affected

MoonLake, Novartis, and UCB are directly affected as sonelokimab challenges their IL-17 inhibitors. Patients with hidradenitis suppurativa (HS) and healthcare providers seeking effective treatments are also impacted.

Market Impact

• MoonLake's sonelokimab challenges Novartis's secukinumab and UCB's bimekizumab in the HS treatment market.
• The adolescent data adds a strategic dimension, potentially interrupting disease progression in younger patients.
• A successful BLA submission in September 2026 could reset market differentiation.

What to Watch

Key focus is on MoonLake's BLA submission by September 2026, incorporating adult Week 52 data and VELA-TEEN results. A complete, on-time filing will validate regulatory confidence and set the FDA review clock in motion.